Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
P 2 (3)
P 3 (3)

Trial Status

Recruiting6
Not Yet Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT07325539Phase 2Recruiting

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

NCT07559877Phase 3RecruitingPrimary

Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:

NCT07392320Phase 2RecruitingPrimary

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

NCT07332247Phase 2RecruitingPrimary

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

NCT07238569Phase 3Not Yet Recruiting

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

NCT07235319Phase 3RecruitingPrimary

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

Showing all 7 trials

Research Network

Activity Timeline